세계의 안티센스 및 RNAi 치료제 시장 : 기술, 투여 경로, 용도, 최종 사용자별 예측(2025-2030년)

The Antisense & RNAi Therapeutics Market was valued at USD 4.43 billion in 2023, expected to reach USD 5.07 billion in 2024, and is projected to grow at a CAGR of 14.64%, to USD 11.54 billion by 2030.

Antisense and RNA interference (RNAi) therapeutics represent a groundbreaking segment in biopharmaceuticals focused on gene expression modulation. By turning off specific genes, these therapies offer promising applications across various diseases, particularly genetic disorders, cancers, and neurological conditions. The necessity of these therapies arises from unmet clinical needs, such as treating rare genetic maladies for which traditional therapies fall short. Key end-use applications include clinical research, hospital treatments, and specialty clinics, where targeted gene therapy offers more precise treatment options. Market growth is fueled by factors such as increased investment in genomic research, technological advancements in RNA-based therapeutics, and a rising prevalence of genetic disorders. Regulatory support and collaborations among key biotech companies also add momentum. Major opportunities lie in diversifying RNAi platforms and expanding therapeutic targeting beyond liver and ocular delivery to include widespread tissue distribution. However, growth is restrained by factors like high development costs, stringent regulatory requirements, and challenges in delivery mechanisms like off-target effects and immune responses. These constraints necessitate innovative delivery systems and synthetic biology advancements to enhance therapeutic efficacy and safety. Innovation in this arena could capitalize on the integration of AI and machine learning to better predict gene targets and improve design specificity. The business growth potential is considerable for companies investing in robust R&D pipelines, strategic partnerships, and IP development for proprietary RNAi platforms. The dynamic nature of the market, characterized by rapid technological shifts and intensive competition, demands nimble adaptation and responsiveness to emerging scientific developments. Future research should focus on optimizing delivery vehicles and expanding the therapeutic index, enhancing long-term sustainability and marketable success. Businesses should also actively monitor changes in regulatory landscapes to adjust strategies and leverage market acceleration effectively.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Antisense & RNAi Therapeutics Market

The Antisense & RNAi Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing prevalence of genetic disorders worldwide
  • Rise in R&D activities on antisense and RNAi-based therapies
• Market Restraints
  • High cost of manufacturing antisense-RNAi-therapeutics
• Market Opportunities
  • Collaboration between biotech companies and academic institutions accelerates for antisense & RNAi therapeutics research
  • Rising awareness about personalized medicine
• Market Challenges
  • Concerns associated with the efficacy of antisense-RNAi-therapeutics

Porter's Five Forces: A Strategic Tool for Navigating the Antisense & RNAi Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Antisense & RNAi Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Antisense & RNAi Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Antisense & RNAi Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Antisense & RNAi Therapeutics Market

A detailed market share analysis in the Antisense & RNAi Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Antisense & RNAi Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Antisense & RNAi Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Antisense & RNAi Therapeutics Market

A strategic analysis of the Antisense & RNAi Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Antisense & RNAi Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Alnylam Pharmaceuticals, Inc., Amarna Therapeutics BV, Arbutus Biopharma Corporation, Arrowhead Pharmaceuticals, Inc., AstraZeneca plc, Benitec Biopharma Limited, Carisma Therapeutics Inc., Evox Therapeutics Ltd, GenScript Biotech Corporation, Ionis Pharmaceuticals, Inc., Novo Nordisk A/S, Regenxbio Inc., Sanofi S.A., Silence Therapeutics plc, Sirnaomics, Inc., Viridian Therapeutics, Inc., and Wave Life Sciences Ltd.

Market Segmentation & Coverage

This research report categorizes the Antisense & RNAi Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Technology, market is studied across Antisense RNA and RNA Interference. The RNA Interference is further studied across miRNA and siRNA.
• Based on Route of Administration, market is studied across Intra-dermal Injections, Intraperitoneal Injections, Intravenous Injections, Pulmonary Delivery, and Topical Delivery.
• Based on Application, market is studied across Cardiovascular Diseases (CVDs), Genetic Disorders, Infectious Diseases, Neurodegenerative Disorders, Oncology, Renal Diseases, and Respiratory Disorders.
• Based on End User, market is studied across Hospitals:, Pharmaceutical & Biotechnology Companies, Research & Academic Institutes, and Specialty Clinics.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of genetic disorders worldwide
    • 5.1.1.2. Rise in R&D activities on antisense and RNAi-based therapies
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of manufacturing antisense-RNAi-therapeutics
  • 5.1.3. Opportunities
    • 5.1.3.1. Collaboration between biotech companies and academic institutions accelerates for antisense & RNAi therapeutics research
    • 5.1.3.2. Rising awareness about personalized medicine
  • 5.1.4. Challenges
    • 5.1.4.1. Concerns associated with the efficacy of antisense-RNAi-therapeutics
• 5.2. Market Segmentation Analysis
  • 5.2.1. Technology: increasing adoption of RNA interference owing to precise genetic targeting
  • 5.2.2. Application: Boosting applications of antisense & RNAi therapeutics in oncology due to targeting cancer-specific mutations
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Antisense & RNAi Therapeutics Market, by Technology

• 6.1. Introduction
• 6.2. Antisense RNA
• 6.3. RNA Interference
  • 6.3.1. miRNA
  • 6.3.2. siRNA

7. Antisense & RNAi Therapeutics Market, by Route of Administration

• 7.1. Introduction
• 7.2. Intra-dermal Injections
• 7.3. Intraperitoneal Injections
• 7.4. Intravenous Injections
• 7.5. Pulmonary Delivery
• 7.6. Topical Delivery

8. Antisense & RNAi Therapeutics Market, by Application

• 8.1. Introduction
• 8.2. Cardiovascular Diseases (CVDs)
• 8.3. Genetic Disorders
• 8.4. Infectious Diseases
• 8.5. Neurodegenerative Disorders
• 8.6. Oncology
• 8.7. Renal Diseases
• 8.8. Respiratory Disorders

9. Antisense & RNAi Therapeutics Market, by End User

• 9.1. Introduction

9.2. Hospitals:

• 9.3. Pharmaceutical & Biotechnology Companies
• 9.4. Research & Academic Institutes
• 9.5. Specialty Clinics

10. Americas Antisense & RNAi Therapeutics Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Antisense & RNAi Therapeutics Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Antisense & RNAi Therapeutics Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. Sirnaomics Ltd. showcased innovative galAhead muRNA technology at the 2024 OPT congress in Boston
  • 13.3.2. Ribocure Pharmaceuticals AB and Boehringer Ingelheim International GmbH partner to develop innovative RNAi-based treatments
  • 13.3.3. Shanghai Argo Biopharmaceutical Co., Ltd. partnered with Novartis AG in a Landmark USD 4.165 Billion deal to advance RNAi therapeutics for cardiovascular diseases
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Alnylam Pharmaceuticals, Inc.
• 2. Amarna Therapeutics BV
• 3. Arbutus Biopharma Corporation
• 4. Arrowhead Pharmaceuticals, Inc.
• 5. AstraZeneca plc
• 6. Benitec Biopharma Limited
• 7. Carisma Therapeutics Inc.
• 8. Evox Therapeutics Ltd
• 9. GenScript Biotech Corporation
• 10. Ionis Pharmaceuticals, Inc.
• 11. Novo Nordisk A/S
• 12. Regenxbio Inc.
• 13. Sanofi S.A.
• 14. Silence Therapeutics plc
• 15. Sirnaomics, Inc.
• 16. Viridian Therapeutics, Inc.
• 17. Wave Life Sciences Ltd